Biora Therapeutics, Inc. (NASDAQ:BIOR) Q4 2023 Results Conference Call March 26, 2024 4:30 PM ET

Company Participants

Chuck Pedala - LifeSci Advisors
Adi Mohanty - CEO
Ariella Kelman - Chief Medical Officer
Eric d'Esparbes - CFO

Conference Call Participants

John Vandermosten - Zacks Investment Research

Operator

Welcome to the Biora Therapeutics Fourth Quarter 2023 Financial Results Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow a formal presentation. [Operator Instructions]. As a reminder, this conference is being recorded.

I will now turn the call over to Chuck Pedala, Managing Director with LifeSci Advisors, Biora's Investor Relations Firm.

Chuck Pedala

Thank you, Operator. Good afternoon and welcome to the Biora Therapeutics fourth quarter 2023 Corporate Update and Financial Results conference call. Joining me on the call are Adi Mohanty, Chief Executive Officer; Ariella Kelman, Chief Medical Officer; and Eric d'Esparbes, Chief Financial Officer.

Before I turn the call over to Mr. Mohanty, I'd like to remind you that today's call will include forward-looking statements within the meeting of the Federal Securities Law, including but not limited to, the types of statements identified as forward-looking in our quarterly report on Form 10-K that we plan to file in the next few days and our subsequent reports filed with the SEC, which are available on our website in the Investors section.

These forward-looking statements represent our views only as of the date of this call and involve substantial risks and uncertainties, including many that are beyond our control. Please note that the actual results could differ materially from those expressed in the forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements as well as risks related to our business, please see the company's periodic reports filed with the SEC.

With that, I will now turn the call over to Adi Mohanty, CEO of Biora Therapeutics. Adi?

Adi Mohanty

Thanks, Chuck, and thank you, everyone, for joining us. The fourth quarter capped a transformational year for Biora. We made excellent progress with both our platform technologies as we continued our strong execution. The NaviCap platform continues to hit its lodestones. As forecasted, we achieved clearance of our IND by the FDA, and we initiated our BT-600 clinical trial, which we believe to be the first clinical trial in the U.S. for an ingestible drug-device combination.